chartexchange

Leqembi® Pen subcutaneous treatment launched in Japan

PR Newswire | Nov 13, 2026 2:11 AM EST

STOCKHOLM, Nov. 13, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today announced that Leqembi Pen, the subcutaneous formulation of lecanemab, has been launched in Japan for the treatment of early Alzheimer's disease. Japan is the second country,...

Read original article